2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Transplantation, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Genetic Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, MDS, MPN, CML, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2838 Superior survival in patients with polycythemia vera taking GLP-1 receptor agonist therapy

Esteban Toro Velez, MD, Carolina Velez-Mejia, MD2, Keri Zhou3, Ruchi Desai, MD4
1 Virginia Commonwealth University, Richmond, Virginia, United States
2 Virginia Commonwealth University, Richmond, Virginia, United States
3 Virginia Commonwealth University, Richmond, Virginia, United States
4 Virginia Commonwealth University, Richmond, Virginia, United States

Background:

Glucagon-like peptide-1 receptor agonists (GLP1) were originally intended for metabolic purposes, recent data has emerged showing them as potent immunomodulatory agents with important effects in cancer care. Polycythemia Vera (PV) is a clonal hematopoietic stem cell disorder characterized by driver mutations associated with a hyperinflammatory bone marrow microenvironment. While cytoreductive therapies and antiplatelet agents successfully mitigate acute thrombotic risk, there is a need to improve long term disease control and outcomes for patients. To our knowledge, this is the first large-scale real-world study to specifically address survival outcomes in patients with PV taking GLP1.

 

Methods:

A retrospective cohort study using the TriNetX Research Network from 145 healthcare organizations from the Global Collaborative Network was carried out. We included patients ≥ 18 years diagnosed with PV using the ICD-10 code between January 01, 2005 to June 30, 2026 who received systemic therapy including hydroxyurea, interferon alpha 2a/2b, ropeginterefon alpha-2b or ruxolitinib. After the diagnosis and starting appropriate treatment, patients were divided into whether they received a GLP1 or not. The only variable different among comparison groups was the presence or absence of the GLP1. Cohorts were balanced using propensity score matching for age at diagnosis, female, Black race, Hispanics, hemoglobin, platelet count, body mass index, comorbidities, and concomitant medications. Kaplan-Meier survival curves were used to assess overall survival (OS) over a 10 year follow up period.

 

Results:

A total of 10,897 patients were identified, of these 448 patients started GLP1 after the diagnosis and 10,449 were not on GLP1. After balancing each cohort had a total of 440 patients.

 

Patients with PV who were taking a GLP1 had better OS than those who did not [p-value of 0.0002, HR 0.417, CI 0.258,0.674]. At 10 years the median overall survival for both groups was not reached, however, the survival probability was noted to be 87% vs 69%, respectively.

 

The risk for developing thromboembolic complications had a tendency to be less in those taking GLP1, however, this was not yet statistically significant (6.6% vs 8.4% HR 0.672, CI 0.398,1.135). No difference was seen in the risk for bleeding or myelofibrosis among both groups.

 

Conclusions:

Patients with PV receiving GLP1 therapy demonstrated superior overall survival. This survival advantage may be driven by GLP1 anti-inflammatory properties, by interrupting the chronic thrombo-inflammatory environment as well as possibly slowing the clonal evolution and proliferation. Despite the limitations inherent to TriNetX data, such as reliance on administrative coding accuracy and lack of clinical details, GLP1 therapy causes extended survival for those with PV. This treatment has promising effects for patients and represents a novel therapeutic avenue in cancer care. Therefore, evaluating GLP1 as a possible disease-modifying agent in PV via prospective clinical trials are needed.

Esteban Toro Velez, MD: No relevant conflicts of interest to declare.